Tags

Type your tag names separated by a space and hit enter

[Enalapril treatment of residual pulmonary hypertension in patients operated rheumatic mitral valve defects].
Klin Med (Mosk). 2000; 78(2):40-2.KM

Abstract

A pilot trial of efficiency of enalapril maleate in the treatment of residual pulmonary hypertension was made in 22 patients operated for rheumatic mitral valve defects. Degree I, II and III of pulmonary hypertension was registered in 5, 13 and 4 patients, respectively. Thus, the patients had NYHA functional classes III and IV (22.7 and 77.3%, respectively. Enalapril given for 6 months in a mean daily dose 12.3 +/- 1.57 mg/m2 (5-30 mg a day) normalized pressure in the pulmonary artery in 18.2% of patients. 50% of patients showed hypertension degree I, only one female retained hypertension degree III. To the end of the treatment the functional classes were the following: II--in 68.2%, III--in 27.3% and IV--in 4.5%.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article

Language

rus

PubMed ID

10723151

Citation

Privalova, E V., et al. "[Enalapril Treatment of Residual Pulmonary Hypertension in Patients Operated Rheumatic Mitral Valve Defects]." Klinicheskaia Meditsina, vol. 78, no. 2, 2000, pp. 40-2.
Privalova EV, Ershov VI, Ermakov AI, et al. [Enalapril treatment of residual pulmonary hypertension in patients operated rheumatic mitral valve defects]. Klin Med (Mosk). 2000;78(2):40-2.
Privalova, E. V., Ershov, V. I., Ermakov, A. I., Ivanov, A. S., Baloian, G. M., Kulagina, T. I., Aksiuk, M. A., & Dobrovol'skaia, T. N. (2000). [Enalapril treatment of residual pulmonary hypertension in patients operated rheumatic mitral valve defects]. Klinicheskaia Meditsina, 78(2), 40-2.
Privalova EV, et al. [Enalapril Treatment of Residual Pulmonary Hypertension in Patients Operated Rheumatic Mitral Valve Defects]. Klin Med (Mosk). 2000;78(2):40-2. PubMed PMID: 10723151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Enalapril treatment of residual pulmonary hypertension in patients operated rheumatic mitral valve defects]. AU - Privalova,E V, AU - Ershov,V I, AU - Ermakov,A I, AU - Ivanov,A S, AU - Baloian,G M, AU - Kulagina,T I, AU - Aksiuk,M A, AU - Dobrovol'skaia,T N, PY - 2000/3/21/pubmed PY - 2000/4/15/medline PY - 2000/3/21/entrez SP - 40 EP - 2 JF - Klinicheskaia meditsina JO - Klin Med (Mosk) VL - 78 IS - 2 N2 - A pilot trial of efficiency of enalapril maleate in the treatment of residual pulmonary hypertension was made in 22 patients operated for rheumatic mitral valve defects. Degree I, II and III of pulmonary hypertension was registered in 5, 13 and 4 patients, respectively. Thus, the patients had NYHA functional classes III and IV (22.7 and 77.3%, respectively. Enalapril given for 6 months in a mean daily dose 12.3 +/- 1.57 mg/m2 (5-30 mg a day) normalized pressure in the pulmonary artery in 18.2% of patients. 50% of patients showed hypertension degree I, only one female retained hypertension degree III. To the end of the treatment the functional classes were the following: II--in 68.2%, III--in 27.3% and IV--in 4.5%. SN - 0023-2149 UR - https://www.unboundmedicine.com/medline/citation/10723151/[Enalapril_treatment_of_residual_pulmonary_hypertension_in_patients_operated_rheumatic_mitral_valve_defects]_ L2 - http://www.diseaseinfosearch.org/result/6088 DB - PRIME DP - Unbound Medicine ER -